Skip to main content

Table 1 Comparison of clinicopathological characteristics of 843 HER2-positive patients

From: Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

FactorsWithout trastuzumabWith trastuzumabp-value
Group 1
n(%)
Group 2
n(%)
Group 3
n(%)
Age (year)
  ≤ 4031 (12.2)76 (25.9)44 (15.0)< 0.001
  > 40224 (87.8)218 (74.1)250 (85.0) 
T stage
 T151 (20.0)70 (23.8)64 (21.8)0.044
 T2172 (67.5)172 (58.5)200 (68.0) 
 T3–432 (12.5)52 (17.7)30 (10.2) 
N stage
 pN0144 (56.5)162 (55.1)152 (51.7)0.217
 pN176 (29.8)78 (26.5)79 (26.9) 
 pN2–335 (13.7)54 (18.4)63 (21.4) 
Histological grade
 1~2198 (77.6)246 (83.7)242 (82.3)0.171
 357 (22.4)48 (16.3)52 (17.7) 
HR
 Negative145 (56.9)164 (55.8)164 (55.8)0.957
 Positive110 (43.1)130 (44.2)130 (44.2) 
Ki67 (%)
  < 3067 (52.8)134 (45.6)132 (44.9)0.187
  ≥ 3060 (47.2)160 (54.4)162 (55.1) 
NC
 No117 (45.9)128 (43.5)130 (44.2)0.853
 Yes138 (54.1)166 (56.5)164 (55.8) 
Total255 (100.0)294 (100.0)294 (100.0) 
  1. Group 1 contained patients without trastuzuamb treatment, group 2 contained patients with trastuzuamb and low pre-NLR value, and group 3 contained patients with trastuzuamb and high pre-NLR value. Statistically significant factors are in bold font. NLR, neutrophil/lymphocyte ratio; HR, hormone receptor; NC, neoadjuvant chemotherapy